Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.06) by 83.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $14.200 million which missed the analyst consensus estimate of $16.475 million by 13.81 percent. This is a 88.05 percent increase over sales of $7.551 million the same period last year.